ResearcherUniversity Hospital of BaselNo recent work listed
Richard Herrmann
Matched on OpenAlex author ID A5109085182. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 31
2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper
Papers 3
- Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre pha… Co-author DOI 10.1177/1758835918818351↗
- Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
- Clinical benefit response in pancreatic cancer trials revisited. Last author DOI 10.1159/000357965↗
Closest collaborators
The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Werner Scheithauer · 3 shared papers, 2014–2019 · strength 0.20
- Paper Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine… DOI 10.1177/1758835918818351↗
- Paper Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresec… DOI 10.1016/s1470-2045(18)30098-6↗
- Paper Clinical benefit response in pancreatic cancer trials revisited. DOI 10.1159/000357965↗
- Bengt L. G. Glimelius · 3 shared papers, 2014–2019 · strength 0.20
- Paper Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine… DOI 10.1177/1758835918818351↗
- Paper Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresec… DOI 10.1016/s1470-2045(18)30098-6↗
- Paper Clinical benefit response in pancreatic cancer trials revisited. DOI 10.1159/000357965↗
- Gyorgy Bodoky · 2 shared papers, 2014–2019 · strength 0.14
- Peter Brauchli · 1 shared paper, 2019 · strength 0.09
- Piera Gargiulo · 1 shared paper, 2019 · strength 0.09
- Franck Bonnetain · 1 shared paper, 2018 · strength 0.05
- Helmut Frieß · 1 shared paper, 2018 · strength 0.05
- G. Deplanque · 1 shared paper, 2018 · strength 0.05
- L. Bengt van Rijssen · 1 shared paper, 2018 · strength 0.05
- David Goldstein · 1 shared paper, 2018 · strength 0.05
- Roberto Labianca · 1 shared paper, 2018 · strength 0.05
- Thierry Conroy · 1 shared paper, 2018 · strength 0.05
- Emil ter Veer · 1 shared paper, 2018 · strength 0.05
- Jean‐Luc Van Laethem · 1 shared paper, 2018 · strength 0.05
- Johanna W. Wilmink · 1 shared paper, 2018 · strength 0.05
- Eileen Mary O'Reilly · 1 shared paper, 2018 · strength 0.05
- Ian Chau · 1 shared paper, 2018 · strength 0.05
- Hanneke W.M. van Laarhoven · 1 shared paper, 2018 · strength 0.05
- Chris Verslype · 1 shared paper, 2018 · strength 0.05
- John P. Neoptolemos · 1 shared paper, 2018 · strength 0.05
- Marc G. Besselink · 1 shared paper, 2018 · strength 0.05
- Jens Thomas Siveke · 1 shared paper, 2018 · strength 0.05
- Takuji Okusaka · 1 shared paper, 2018 · strength 0.05
- Uwe Pelzer · 1 shared paper, 2018 · strength 0.05
- Jordan D. Berlin · 1 shared paper, 2018 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.